Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 18 April 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) will move forward with a survey of healthcare professionals regarding their opinions and perceptions about prescription drug promotion after receiving approval from the Office of Management and Budget (OMB), the executive branch's regulatory clearing house.
FDA's intent to conduct the survey was first announced in January 2012, when it said in a Federal Register posting that it was soliciting comments on a proposed study entitled "Health Care Professional Survey of Prescription Drug Promotion."
Comments on the proposal were for 60 days, and the proposal was finally sent to OMB for final approved in October 2012.
As Regulatory Focus explained at the time, FDA's study summary explained that consumers and providers alike are subject to direct-to-consumer (DTC) advertising from pharmaceutical companies, and that questions have been raised regarding the influence of these commercials on patient care.
The proposed survey will specifically look at the effects of DTC advertising on so-called "physician extenders"- nurses and physician assistants-that FDA says are providing an "increasingly vital role in primary care delivery." An earlier 2002 study did not include physician extenders, but instead focused on general practitioners and specialists.
"Because DTC advertising likely affects daily interactions between patients and nurse practitioners and physician assistants […] including these groups in the new sample will further understanding of DTC advertising in the healthcare system," FDA explained. The proposed study would also weight the race, age and sex of respondents to better reflect national demographic patterns.
The study is also slated to include a look at how social media is affecting healthcare professionals' prescribing habits, and FDA said its intent was to gain an awareness of "new and merging promotional sites and practices."
The proposal received several comments from industry, including from heavyweights Merck and Bausch + Lomb.
Merck said that while it was supportive of FDA's efforts to "gather more evidence on the influence of DTC advertising and prescription drug promotion on interactions between patients and their healthcare providers," it nevertheless had several problems with the study as originally designed.
For example, Merck said the proposed language was unclear as to which specialists would be looked at in the study, and did not define general practitioners. Neither did it specify inclusion criteria in the study, leaving open the prospect that low-prescribing entities could influence the study's outcome.
Merck also said that it hoped FDA would attempt to gather more information about the effects of advertising on prescribing decisions, including how often prescribed products wound up being switched for their generic equivalents at the pharmacy. The company said it favored language that would ask, "On a typical day, for how many of your prescriptions written do you get a call from a pharmacy asking for authorization to switch to another branded product?"
This could change the overall effect of DTC advertising on true prescribing habits, the company said.
Bausch + Lomb's comments, meanwhile, focused on the specific wording of questions to be asked in the study. The company did, however, recommend excluding all seven questions on the effects of social media on prescribing habits, arguing that the questions were "outside the scope of this survey."
Now the question is whether or not FDA adopted any of those recommendations or conceded any of industry's concerns.
FDA's 18 April 2013 Federal Register posting explains only that OMB approved the survey, but does not mention if any changes were made in advance of its submission to OMB. The OMB change control document notes that the survey was approved with changes by OMB's Dominic Mancini, acting deputy administrator of the Office of Information and Regulatory Affairs (OIRA). Those changes, however, were not outlined.
One interesting point of information, however, is the study's cost. FDA will be spending $364,588 to gather the information.
The study expires on 29 February 2016, but FDA said it anticipates concluding the study within 24 months of approval, or by March 2015.
Tags: DTC, Latest News, advertising, promotion, social media
Regulatory Focus newsletters
All the biggest regulatory news and happenings.